Statera Biopharma, Inc.
STAB · OTC
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.01 | 0.00 | -0.00 |
| FCF Yield | -12.29% | -1.19% | -31.27% | -10.19% |
| EV / EBITDA | -9.91 | -7.77 | -2.93 | -1.30 |
| Quality | ||||
| ROIC | 86.05% | -532.43% | -161.93% | -523.12% |
| Gross Margin | 74.74% | 73.86% | 64.56% | 70.22% |
| Cash Conversion Ratio | 0.24 | 0.05 | 0.48 | 0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 287.75% | 271.90% | 1,354,366.23% | 1,141,306.90% |
| Free Cash Flow Growth | -375.65% | 95.53% | 54.19% | 43.32% |
| Safety | ||||
| Net Debt / EBITDA | -5.09 | -2.57 | -1.07 | -0.20 |
| Interest Coverage | -0.85 | -4.48 | -5.77 | -10.09 |
| Efficiency | ||||
| Inventory Turnover | 1.60 | 0.79 | 0.70 | 0.21 |
| Cash Conversion Cycle | -4,216.72 | -3,452.33 | -1,561.38 | -496.36 |